Conference Day Two: Wednesday, May 1, 2024

7:30 am Morning Coffee & Registration

8:15 am Chair’s Opening Remarks

Navigating the Potential of LNP to Understand the Therapeutic Applications to Uncover

8:30 am Capitalizing on CAR-T Therapy as the Next Step in the LNP Development Journey

  • Yanjie Bao Senior Director - Drug Product Development & Manufacturing, Capstan

Synopsis

  •  Revolutionizing the utility of LNPs as the field make significant strides into the cell therapy world 
  • Applying LNP understanding to transfecting primary human T cells in the cell therapy workflow 
  • Evaluating the potential of LNPs as the ‘go-to’ delivery vehicle for CAR-T therapies with a comparison of current vehicles of choice

9:00 am Panel Discussion: The Diary of an LNP Biotech CEO: From Concept to Clinic

Synopsis

  •  Revealing the steps taken to transition from stealth to established to develop LNPs at a biotechnology company 
  • Outlining the priority action points collectively as an industry to drive progress in 2024
  • Discussing interactions with regulatory bodies and the early planning steps taken in anticipation of future submissions

9:30 am Roundtable Discussion: Reaching the Previously Undruggable

Synopsis

  • Unite as an LNP community and discuss the potential of LNPs as the answer to delivering life-saving drugs to regions of the body which were once deemed impossible to reach
  • Debating the next step in the LNP journey to create realistic expectations over the coming 12 months
  • A session coordinated by the morning’s chair will allow for discussions on your tables with feedback to the room, creating an open forum to provide food for thought for all!

10:00 am Morning Break & Speed Networking

Track A: Screening & Delivery

Honing Research into Ligand & PEG Molecules to Maximize LNP Delivery Potential

Download the Full Event Guide for more details


11.15 am Overview of USP’s Standard Setting Process and Evolving approaches to excipient standard setting in support of early-stage drug development

Catherine Sheehan, Senior Director, Foods & Excipients - Global Science & Standards, United States Pharmacopeia (USP)


11.45 am Session Reserved for NANOFCM


12.00 pm Verifying the Role of PEG in the Discovery of LNP & Rationalizing the Obstacles to Overcome

Maple Wang, Principal Scientist, Pfizer


12.30 pm Ask the Speakers

Track B: Formulation & Delivery
Track C: Characterisation & Analytical Development
Track D: Process Development & Manufacturing

12:45 pm Networking Lunch Break

Track A: Screening & Delivery

Evaluating Holistic Methods to Screen for LNP Biodistribution to Drive LNPs to the Previously Unreachable

Download the Full Event Guide for more details


2.00 pm Advancing LNP Screening to Incorporate Automated, High-Throughput Readouts

Marine Hatit, Senior Scientist I, LNP Discovery Lead, Prime Medicine


2.30 pm Addressing the Challenges & Solutions to Overcoming the Blood-Brain Barrier with LNP Drug Products

Rakesh Dixit, CEO, Bionavigen Oncology


3.00 pm Ask the Speakers

Your unique opportunity to ask the speakers your burning questions from the previous sessions in a dedicated Q&A session

Track B: Formulation & Delivery
Track C: Characterisation & Analytical Development
Track D: Process Development & Manufacturing

3:15 pm Afternoon Networking Break

Reviewing the LNP Novel Payloads Across Current Research & Advanced Routes of Administration

4:15 pm Combining p53 mRNA Nanotherapy with Immune Checkpoint Blockade for Liver Cancer

  • Dan G. Duda Director of Translational Research in GI Radiation Oncology and Investigator; Associate Professor of Tumor Biology, Massachusetts General Hospital

Synopsis

  • Outlining how immunotherapy with immune checkpoint blockade (ICB) shows limited benefits in hepatocellular carcinoma (HCC) and other cancers, mediated in part by the immunosuppressive tumour microenvironment (TME)
  • Examining the effects of restoring p53 expression on the immune TME and ICB efficacy
  • Inducing p53 expression in HCC models effectively, eliciting a global reprogramming of cellular and molecular components of the immune TME, combining with ICB

5:00 pm Analyzing the Optimal Route of Administration in Relation to LNP Design, Target Organ & Disease Indication

Synopsis

  • Addressing the breadth of administration routes available for LNPs, including intravenous, intramuscular, subcutaneous and inhalation routes
  • Evaluating the resulting antibody response to LNP administration following differing administration 
  • Correlating the target organ and disease indication severity with route of administration to maximise precise biodistribution

5:30 pm Chair’s Closing Remarks